ValidEoE: Validation in French of a Quality of Life Questionnaire for Patients With Eosinophilic Esophagitis in Pediatrics

Sponsor
Fondation Lenval (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05900011
Collaborator
(none)
100
1
17.1
5.9

Study Details

Study Description

Brief Summary

Eosinophilic esophagitis is a chronic condition of the esophagus. The symptoms of eosinophilic esophagitis can affect the quality of life of affected children. There is no French scale to specifically evaluate the quality of life of these patients.

It will be a monocentric, prospective, descriptive study carried out at the Nice University Hospital.

The main objective of this study will be the validation of a French version of the PedsQL module for eosinophilic esophagitis. It will take place in 2 distinct parts:

  • The translation of the questionnaire in French.

  • Collection of the quality of life questionnaires

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Quality of life questionnaire

Detailed Description

Eosinophilic esophagitis is a chronic pathology of the esophagus. It is the most prevalent condition of chronic esophagitis after gastroesophageal reflux and the largest cause of dysphagia and food impaction in children. Currently the explosion of incidence of cases in the world makes eosinophilic esophagitis a public health issue and a scientific challenge.

In pediatrics, the main symptoms are: dysphagia, feeding difficulties, pyrosis, but also more general symptoms such as: nausea, vomiting or growth retardation. The diagnosis of eosinophilic eosophagitis is mainly made in pathological anatomy on esophageal biopsies. Current recommendations suggest that two to four biopsies should be taken at two different levels (proximal and distal esophagus if possible), even in cases of apparently normal mucosa. The presence of an infiltration of the esophageal mucosa greater than 15 eosinophils per field is mandatory for the diagnosis. In total, the diagnosis is therefore based on anamnestic and histological elements and the absence of other pathology.

Recent French recommendations have led to a consensus on the management of this disease. The therapeutic goal is to achieve clinical and histological remission. Three therapies are currently proposed to patients: proton pump inhibitors, corticosteroids and exclusion diet. The drug treatments used are treatments that have been known for a long time but there is no study that has shown the superiority of one over the other.

Symptoms of eosinophilic esophagitis can affect the quality of life of affected children and their caregivers. The PedsQL Modulates Eosinophilic Esophagitis is a validated, American scale that specifically assesses the quality of life of patients with eosinophilic esophagitis in the pediatric population.

To our knowledge, there is no French scale to specifically assess the quality of life of patients with eosinophilic esophagitis in the pediatric population. The aim of this study is to validate a French and cross-cultural version of the PedsQL quality of life scale for EoE in pediatrics.

It will be a monocentric, prospective, descriptive study carried out at the Nice University Hospital.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Validation in French of a Quality of Life Questionnaire for Patients With Eosinophilic Esophagitis in Pediatrics
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients in the pediatric population with eosinophilic eosphagitis

Patients in the pediatric population with eosinophilic eosiphagitis responding to the PedsQL eosinophilic eosophagitis module

Behavioral: Quality of life questionnaire
Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module

Outcome Measures

Primary Outcome Measures

  1. Measure of quality of life [at inclusion]

    Validation of a French and cross-cultural version of the PedsQL quality of life scale for eosinophilic esophagitis in pediatrics

Secondary Outcome Measures

  1. reliability of the interviewer [through study completion, an average of 1 year]

    Evaluation of the reliability of the interviewer and reliability over time. An evaluation of the structure will be conducted. Sensitivity to change of the questionnaire will be assessed

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
For children :
  • Patients followed at Nice-Lenval University Hospital in pediatric gastroenterology between July 2022 and July 2023

  • Age between 2 and 17 years old

  • Obligation for all patients to be affiliated to social security system

  • Patient followed for eosinophilic esophagitis. Diagnostic criteria for EoE ( compatible symptoms and histological involvement on at least two different esophageal levels: presence of infiltration of the esophageal mucosa greater than 15 eosinophils per field)

  • Acceptance of participation in the study

For parents or representative of parental authority:
  • Parents or representative of parental authority, of a child followed at Lenval Hospital in pediatric gastroenterology for eosinophilic esophagitis

  • Affiliated to a social security system

  • Acceptance of participation in the study

Exclusion Criteria:
  • Intellectual disability, cognitive inability to complete the questionnaire

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopitaux Pediatriques de Nice Chu-Lenval Nice France

Sponsors and Collaborators

  • Fondation Lenval

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondation Lenval
ClinicalTrials.gov Identifier:
NCT05900011
Other Study ID Numbers:
  • 23-HPNCL-01
First Posted:
Jun 12, 2023
Last Update Posted:
Jun 12, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 12, 2023